Intensified chemotherapy without SCT in infant ALL

Results from COG P9407 (Cohort 3)

Zoann E. Dreyer, Joanne M. Hilden, Tamekia Jones, Meenakshi Devidas, Naomi J. Winick, Cheryl L. Willman, Richard C. Harvey, I. Ming Chen, Fred G. Behm, Jeanette Pullen, Brent L. Wood, Andrew J. Carroll, Nyla A. Heerema, Carolyn A. Felix, Blaine Robinson, Gregory H. Reaman, Wanda L. Salzer, Stephen P. Hunger, William L. Carroll, Bruce M. Camitta

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Infants with acute lymphoblastic leukemia (ALL) present with aggressive disease and a poor prognosis. Early relapse within 6-9 months of diagnosis is common. Approximately 75% of infants have MLL-rearranged (MLL-R) ALL with event free survival (EFS) ranging from 20% to 30%. Children's Oncology Group (COG) P9407 used shortened (46 weeks), intensified therapy to address early relapse and poor EFS. Procedure: P9407 therapy was modified three times for induction toxicity resulting in three cohorts of therapy. One hundred forty-seven infants were enrolled in the third cohort. Results: We report an overall 5-year EFS and OS of 42.3±6% and 52.9±6.5% respectively. Poor prognostic factors included age ≤90 days at diagnosis, MLL-R ALL and white cell count ≥50,000/μl. For infants ≤90 days of age, the 5-year EFS was 15.5±10.1% and 48.5±6.7% for those >90 days (P<0.0001). Among infants >90 days of age, 5-year EFS rates were 43.8±8% for MLL-R versus 69.1±13.6% for MLL-germline ALL (P<0.0001). Conclusions: Age ≤90 days at diagnosis was the most important prognostic factor. Despite shortened therapy with early intensification, EFS remained less than 50% overall in MLL-R ALL.

Original languageEnglish (US)
Pages (from-to)419-426
Number of pages8
JournalPediatric Blood and Cancer
Volume62
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Drug Therapy
Recurrence
Therapeutics
Cell Count

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Dreyer, Z. E., Hilden, J. M., Jones, T., Devidas, M., Winick, N. J., Willman, C. L., ... Camitta, B. M. (2015). Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3). Pediatric Blood and Cancer, 62(3), 419-426. https://doi.org/10.1002/pbc.25322

Intensified chemotherapy without SCT in infant ALL : Results from COG P9407 (Cohort 3). / Dreyer, Zoann E.; Hilden, Joanne M.; Jones, Tamekia; Devidas, Meenakshi; Winick, Naomi J.; Willman, Cheryl L.; Harvey, Richard C.; Chen, I. Ming; Behm, Fred G.; Pullen, Jeanette; Wood, Brent L.; Carroll, Andrew J.; Heerema, Nyla A.; Felix, Carolyn A.; Robinson, Blaine; Reaman, Gregory H.; Salzer, Wanda L.; Hunger, Stephen P.; Carroll, William L.; Camitta, Bruce M.

In: Pediatric Blood and Cancer, Vol. 62, No. 3, 01.03.2015, p. 419-426.

Research output: Contribution to journalArticle

Dreyer, ZE, Hilden, JM, Jones, T, Devidas, M, Winick, NJ, Willman, CL, Harvey, RC, Chen, IM, Behm, FG, Pullen, J, Wood, BL, Carroll, AJ, Heerema, NA, Felix, CA, Robinson, B, Reaman, GH, Salzer, WL, Hunger, SP, Carroll, WL & Camitta, BM 2015, 'Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)', Pediatric Blood and Cancer, vol. 62, no. 3, pp. 419-426. https://doi.org/10.1002/pbc.25322
Dreyer, Zoann E. ; Hilden, Joanne M. ; Jones, Tamekia ; Devidas, Meenakshi ; Winick, Naomi J. ; Willman, Cheryl L. ; Harvey, Richard C. ; Chen, I. Ming ; Behm, Fred G. ; Pullen, Jeanette ; Wood, Brent L. ; Carroll, Andrew J. ; Heerema, Nyla A. ; Felix, Carolyn A. ; Robinson, Blaine ; Reaman, Gregory H. ; Salzer, Wanda L. ; Hunger, Stephen P. ; Carroll, William L. ; Camitta, Bruce M. / Intensified chemotherapy without SCT in infant ALL : Results from COG P9407 (Cohort 3). In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 3. pp. 419-426.
@article{28679728072c4594b902e49af6a41155,
title = "Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)",
abstract = "Background: Infants with acute lymphoblastic leukemia (ALL) present with aggressive disease and a poor prognosis. Early relapse within 6-9 months of diagnosis is common. Approximately 75{\%} of infants have MLL-rearranged (MLL-R) ALL with event free survival (EFS) ranging from 20{\%} to 30{\%}. Children's Oncology Group (COG) P9407 used shortened (46 weeks), intensified therapy to address early relapse and poor EFS. Procedure: P9407 therapy was modified three times for induction toxicity resulting in three cohorts of therapy. One hundred forty-seven infants were enrolled in the third cohort. Results: We report an overall 5-year EFS and OS of 42.3±6{\%} and 52.9±6.5{\%} respectively. Poor prognostic factors included age ≤90 days at diagnosis, MLL-R ALL and white cell count ≥50,000/μl. For infants ≤90 days of age, the 5-year EFS was 15.5±10.1{\%} and 48.5±6.7{\%} for those >90 days (P<0.0001). Among infants >90 days of age, 5-year EFS rates were 43.8±8{\%} for MLL-R versus 69.1±13.6{\%} for MLL-germline ALL (P<0.0001). Conclusions: Age ≤90 days at diagnosis was the most important prognostic factor. Despite shortened therapy with early intensification, EFS remained less than 50{\%} overall in MLL-R ALL.",
author = "Dreyer, {Zoann E.} and Hilden, {Joanne M.} and Tamekia Jones and Meenakshi Devidas and Winick, {Naomi J.} and Willman, {Cheryl L.} and Harvey, {Richard C.} and Chen, {I. Ming} and Behm, {Fred G.} and Jeanette Pullen and Wood, {Brent L.} and Carroll, {Andrew J.} and Heerema, {Nyla A.} and Felix, {Carolyn A.} and Blaine Robinson and Reaman, {Gregory H.} and Salzer, {Wanda L.} and Hunger, {Stephen P.} and Carroll, {William L.} and Camitta, {Bruce M.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/pbc.25322",
language = "English (US)",
volume = "62",
pages = "419--426",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Intensified chemotherapy without SCT in infant ALL

T2 - Results from COG P9407 (Cohort 3)

AU - Dreyer, Zoann E.

AU - Hilden, Joanne M.

AU - Jones, Tamekia

AU - Devidas, Meenakshi

AU - Winick, Naomi J.

AU - Willman, Cheryl L.

AU - Harvey, Richard C.

AU - Chen, I. Ming

AU - Behm, Fred G.

AU - Pullen, Jeanette

AU - Wood, Brent L.

AU - Carroll, Andrew J.

AU - Heerema, Nyla A.

AU - Felix, Carolyn A.

AU - Robinson, Blaine

AU - Reaman, Gregory H.

AU - Salzer, Wanda L.

AU - Hunger, Stephen P.

AU - Carroll, William L.

AU - Camitta, Bruce M.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: Infants with acute lymphoblastic leukemia (ALL) present with aggressive disease and a poor prognosis. Early relapse within 6-9 months of diagnosis is common. Approximately 75% of infants have MLL-rearranged (MLL-R) ALL with event free survival (EFS) ranging from 20% to 30%. Children's Oncology Group (COG) P9407 used shortened (46 weeks), intensified therapy to address early relapse and poor EFS. Procedure: P9407 therapy was modified three times for induction toxicity resulting in three cohorts of therapy. One hundred forty-seven infants were enrolled in the third cohort. Results: We report an overall 5-year EFS and OS of 42.3±6% and 52.9±6.5% respectively. Poor prognostic factors included age ≤90 days at diagnosis, MLL-R ALL and white cell count ≥50,000/μl. For infants ≤90 days of age, the 5-year EFS was 15.5±10.1% and 48.5±6.7% for those >90 days (P<0.0001). Among infants >90 days of age, 5-year EFS rates were 43.8±8% for MLL-R versus 69.1±13.6% for MLL-germline ALL (P<0.0001). Conclusions: Age ≤90 days at diagnosis was the most important prognostic factor. Despite shortened therapy with early intensification, EFS remained less than 50% overall in MLL-R ALL.

AB - Background: Infants with acute lymphoblastic leukemia (ALL) present with aggressive disease and a poor prognosis. Early relapse within 6-9 months of diagnosis is common. Approximately 75% of infants have MLL-rearranged (MLL-R) ALL with event free survival (EFS) ranging from 20% to 30%. Children's Oncology Group (COG) P9407 used shortened (46 weeks), intensified therapy to address early relapse and poor EFS. Procedure: P9407 therapy was modified three times for induction toxicity resulting in three cohorts of therapy. One hundred forty-seven infants were enrolled in the third cohort. Results: We report an overall 5-year EFS and OS of 42.3±6% and 52.9±6.5% respectively. Poor prognostic factors included age ≤90 days at diagnosis, MLL-R ALL and white cell count ≥50,000/μl. For infants ≤90 days of age, the 5-year EFS was 15.5±10.1% and 48.5±6.7% for those >90 days (P<0.0001). Among infants >90 days of age, 5-year EFS rates were 43.8±8% for MLL-R versus 69.1±13.6% for MLL-germline ALL (P<0.0001). Conclusions: Age ≤90 days at diagnosis was the most important prognostic factor. Despite shortened therapy with early intensification, EFS remained less than 50% overall in MLL-R ALL.

UR - http://www.scopus.com/inward/record.url?scp=84921437872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921437872&partnerID=8YFLogxK

U2 - 10.1002/pbc.25322

DO - 10.1002/pbc.25322

M3 - Article

VL - 62

SP - 419

EP - 426

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -